|
|
Article: King Pharmaceuticals Licenses Exclusive Rights to CYANOKIT[R] in U.S.
- Article from:
- Bioterrorism Week
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
King Pharmaceuticals, Inc. (NYSE:KG) announced that it has licensed from Merck Sante S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany, the exclusive rights to market and sell CYANOKIT[R] 5 g (hydroxocobalamin for injection) ANTIDOTE in the U.S. CYANOKIT[R] is indicated for the treatment of known or suspected cyanide poisoning, typically caused by smoke inhalation from fires (see also King Pharmaceuticals, Inc.).
"CYANOKIT[R] is well-suited to King's existing line of acute care products," said Brian A. Markison, Chairman, President and CEO. "Our portfolio of antidotes currently serves the emergency medical services community, as well as the U.S. Department ...